RP-6306 in Patients With Advanced Cancer
Canadian Cancer Trials Group
Canadian Cancer Trials Group
Bristol-Myers Squibb
Duke University
Bristol-Myers Squibb
Bristol-Myers Squibb
Agenus Inc.
Prescient Therapeutics, Ltd.
ElmediX
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Bristol-Myers Squibb
Mayo Clinic
Akeso
Institut du Cancer de Montpellier - Val d'Aurelle
Duke-NUS Graduate Medical School
Dana-Farber Cancer Institute
Massachusetts General Hospital
Royal Marsden NHS Foundation Trust
Royal Marsden NHS Foundation Trust
Eli Lilly and Company
University of Colorado, Denver
iTeos Therapeutics
West China Hospital
University Health Network, Toronto
Mayo Clinic
Bayer
M.D. Anderson Cancer Center
Duke University
School of Health Sciences Geneva
M.D. Anderson Cancer Center
REHPA, The Danish Knowledge Centre for Rehabilitation and Palliative Care
Dartmouth-Hitchcock Medical Center
CASI Pharmaceuticals, Inc.
Bristol-Myers Squibb
M.D. Anderson Cancer Center
Massachusetts General Hospital
Merck Sharp & Dohme LLC
The University of Hong Kong
CStone Pharmaceuticals
Peter MacCallum Cancer Centre, Australia
Bristol-Myers Squibb
Bristol-Myers Squibb
CStone Pharmaceuticals
M.D. Anderson Cancer Center
Five Prime Therapeutics, Inc.
Massachusetts General Hospital
BeiGene
Bristol-Myers Squibb
Vietnam Palliative Health Care Society
Bristol-Myers Squibb
Eli Lilly and Company